The pathology and politics of dysplasia in ulcerative colitis

Current Opinion in Gastroenterology

Volumn 14, Issue 1, 1998, Pages 11-14

  Wright, Cheryl L ^a   Riddell, Robert H ^b  

^a Medlab ^*  (New Zealand)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOCHEMICAL MARKER; FATTY ACID SYNTHASE; FOLIC ACID; KI 67 ANTIGEN; MATRIX PROTEIN; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA1;

BLOOD LEVEL; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CELL NUCLEUS MATRIX; CHEMOPROPHYLAXIS; CHRONIC DISEASE; CLINICAL RESEARCH; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; DIET SUPPLEMENTATION; DISEASE MARKER; DNA METHYLATION; DRUG TARGETING; DYSPLASIA; FATTY ACID METABOLISM; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HIGH RISK POPULATION; HUMAN; ILEUM POUCH; NEOPLASM; NONHUMAN; PATHOLOGY; PATIENT; PATIENT EDUCATION; PATIENT MONITORING; SERUM; SHORT SURVEY; TISSUE LEVEL; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

EID: 0031973718     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199801000-00003     Document Type: Short Survey

References (27)

1. Morson BC, Pang LSC: Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 1967, 8:423-434.
2. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, et al.: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968.
3. Axon ATR: Screening and surveillance of ulcerative colitis. Gastrointest Endosc Clin North Am 1997, 7:129-145. A pragmatic descriptive review that discusses the problems of screening and surveillance programs. The author concludes that colonoscopic surveillance, searching for dysplasia, is so far the only practicable approach, but more sensitive and specific methods need to be developed.
4. Goldman H: Significance and detection of dysplasia in chronic colitis. Cancer 1996, 78:2261-2263.
5. Griffiths AM, Sherman PM: Colonoscopic surveillance for cancer in ulcerative colitis: a critical review. J Pediatr Gastroenterol Nutr 1997, 24:202-210. This article applies "rules of evidence" to classify quality of design and results of studies of the last 20 years, and concludes that there is "fair evidence" to support recommendations that colonoscopic surveillance be continued.
6. Harpaz N, Talbot IC: Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 1996, 13:339-357.
7. Itzkowitz SH: Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 1997, 26:129-139.
8. Sonnenberg A, El-Serag HB: Economic aspects of endoscopic screening for intestinal precancerous conditions. Gastrointest Endosc Clin North Am 1997, 7:165-184.
9. Noffsinger AE, Miller MA, Cusi MV, Fenoglio-Preiser CM: The pattern of cell proliferation in neoplastic and non-neoplastic lesions of ulcerative colitis. Cancer 1996, 78:2307-2312. Ki-67 immunohistochemical staining may help to differentiate dysplasia from regenerative changes.
10. Izzo RX, Pellecchia C: Dysplasia expresses altered nuclear matrix protein composition in human ulcerative colitis. Biochemistry & Molecular Biology International 1996, 40:521-526. This article describes proteins found only in dysplastic and cancerous mucosa of UC patients, and not present in normal or nondysplastic UC mucosa. If specific, these proteins may be the first serologic markers of dysplasia in UC.
11. Muscara M, Giuffre G, Barresi G, Tuccari G: The AgNOR count in ulcerative colitis with and without dysplasia. Pathology 1997, 29:136-140.
12. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP, Hamilton SR: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997, 150:201-208.
13. Souza RF, Lei J, Yin J, Appel R, Zou T, Zhou X, Wang S, Rhyu M, Cymes K, Chan O, et al.: A transforming growth factor B1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 1997, 112:40-45.
14. Hoque AT, Hahn SA, Schutte M, Kern SE: DPC4 gene mutation in colitis associated neoplasia. Gut 1997, 40:120-122.
15. Souza FR, Yin J, Smolinski KN, Zou TT, Wang S, Shi YQ, Rhyu MG, Cottrell J, Abraham JM, Biden K, et al.: Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res 1997, 57:2350-2353.
16. Gloria L, Cravo M, Pinto A, Sousa LS, Chaves P, Leitao CN, Quina M, Mira FC, Soares J: DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer 1996, 78:2300-2306.
17. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S: Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996, 39:87-92. Dysplasia and carcinomas were formed within 11 weeks in mice with experimental UC that were pretreated with azoxymethane.
18. Jaramillo E, Watanabe M, Befrits R, Ponce de Leon E, Rubio C, Slezak P: Small, flat colorectal neoplasias in long-standing ulcerative colitis detected by high-resolution electronic video endoscopy. Gastrointest Endosc 1996, 44:15-22.
19. Lindberg B, Persson B, Veress B, Ingelman-Sundberg H, Granqvist S: Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Scand J Gastroenterol 1996, 31:1195-1204. A prospective surveillance of 143 patients with extensive long-standing UC, illustrating that colectomy cannot be delayed once dysplasia is found.
20. Shelton AA, Lehman RE, Schrock TR, Welton ML: Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. Arch Surg 1996, 131:806-811.
21. Leidenius MHK, Farkkila MA, Karkkamen P, Taskinen EI, Kellokumpu IH, Hockerstedt KAV: Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997, 32:706-711. Patients with both UC and primary sclerosing cholangitis had three times the rate of neoplasia than matched patients with UC only.
22. Lashner BA, Provencher KS, Seidner DL, Knesebeck, Brzezinski A: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29-32. A possible protective effect of folic acid supplementation against development of dysplasia or cancer in patients with extensive long-standing UC.
23. Biasco G, Zannoni U, Paganelli GM, Santucci R, Gionchetti P, Rivolta G, Miniero R, Pironi L, Calabrese C, Di Febo G, Miglioli M: Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol Biomarkers Prev 1997, 6:469-471.
24. Gullberg K, Stahlberg D, Liljeqvist L, Tribukait B, Reinholt FP, Veress B, Lofberg R: Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997, 112:1487-1492. Patients with repeated severe pouchitis and subsequent persistent severe pouch atrophy are at high risk of pouch dysplasia.
25. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997, 92:204-211. The American College of Gastroenterology recommends annual surveillance colonoscopies after 8 to 10 years of colitis. The finding of definite dysplasia, of any grade, is an indication for colectomy.
26. Winawer S, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, et al.: Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997, 112:594-642.
27. Robinson RJ, Hart AR, Mayberry JF: Cancer surveillance in ulcerative colitis: a survey of patients knowledge. Endoscopy 1996, 28:761-762.